In the realm of research, efficiency is crucial for achieving produc- tivity. Simplify cell isolation processes to allocate more time to driving scientific breakthroughs! At BIOMEX, we grasp the unique requirements of each application and are ready to support you
in making customized decisions. With our premium products and prompt delivery, we are committed to expediting biomedical research, enhancing data integrity, and easing laboratory work-
loads. Our range includes various positively or negatively selected cell types sourced from peripheral blood, establishing us as the leading provider in mainland Europe.
In our Certificate of Analysis (CoA), we meticulously outline the viability of isolated cells, reinforcing our dedication to transpar- ency and quality assurance.
B cells
B cells have been isolated from mononuclear cells through either positive or negative selection using immunomagnetic cell separa- tion techniques.
In positive selection, the targeted isolation of CD19+ B cells was performed, while in negative selection, other cell types were re- moved to obtain pure CD19+ B cells. These differentiated proce- dures provide our B-cell products with high specificity.
Derived from mononuclear cells, CD19+ B cells play a central role in the immune response by responding to potential threats through the release of antibodies specific to antigens such as bacteria and viruses. The expression of CD19+ facilitates the identification of these B-cells
T cells
Isolated T cells, including CD3+ pan-T cells, CD4+ and CD8+ subgroups, have been obtained through immunomagnetic cell separation techniques employing positive or negative selection from mononuclear cells.
These differentiated procedures ensure the precise isolation of the intended T-cell groups. CD4+ T cells play a role in coordinat- ing immune responses, while CD8+ T cells exert a cytotoxic func- tion.
| Prospective collection of specific subsets of PBMC* | ||
|---|---|---|
| OFFER NO. | PRODUCT | SPECIFICATION |
| 121 94101 010 | Human CD19+ B Cells (neg. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94101 010 | Human CD19+ B cells (neg. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94102 010 | Human CD19+ B cells (pos. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94103 010 | Human CD14+ Monocytes (neg. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94104 010 | Human CD14+ Monocytes (pos. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94105 010 | Human CD56+ NK cells (neg. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94106 010 | Human CD56+ NK cells (pos. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94107 010 | Human Pan-T cells (neg. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94108 010 | Human Pan-T cells (pos. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94109 010 | Human CD4+ T cells (neg. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94110 010 | Human CD4+ T cells (pos. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94111 010 | Human CD8+ T cells (neg. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94112 010 | Human CD8+ T cells (pos. selection), healthy donor | Cryo, 10 × 106 cells/vial |
| 121 94113 010 | Human PBMC, healthy donor, ImmunoSafe-HLA1 | Cryo, 10 Vials PBMCs/10 Patients |
| 121 94114 010 | Human PBMC, healthy donor, ImmunoSafe-HLA2 | Cryo, 10 Vials PBMCs/10 Patients |